Core Points - COSCIENS Biopharma Inc. has appointed Peter H. Puccetti as Interim Chief Executive Officer, succeeding Anna Biehn [1][2] - The leadership transition is part of the company's efforts to reduce costs and streamline its organizational structure while aligning resources with strategic priorities [2] - Puccetti aims to strengthen operational performance and drive shareholder value in his new role [2] Company Overview - COSCIENS is a life science company focused on natural ingredients and pharmaceutical solutions, with a diverse portfolio [3] - The company develops natural, plant-based active ingredients and commercializes pharmaceutical and diagnostic products [3] - COSCIENS' lead pharmaceutical product, Macimorelin, is the first FDA and EMA approved oral test for diagnosing adult growth hormone deficiency [3] Stock Information - COSCIENS' common shares are listed on the Toronto Stock Exchange under the symbol "CSCI" and have a trading symbol "CSCIF" for the OTC market in the United States [4]

Core Insights - COSCIENS Biopharma Inc. has voluntarily delisted from Nasdaq while retaining its listing on the TSX, marking a strategic shift to reduce public reporting obligations in the U.S. [4][5] - The company has successfully implemented a zero-based budgeting initiative, resulting in a 59% reduction in operating expenses compared to Q3 2024, leading to significantly lower cash outflows [3][15] - The gross margins improved by 700 basis points in Q3 2025 due to cost-cutting measures and operational improvements [2][3] Financial Performance - For Q3 2025, COSCIENS reported a consolidated net loss of $1.8 million, a decrease from a net loss of $5.8 million in Q3 2024, reflecting a $4.0 million improvement [15][18] - Total revenue for Q3 2025 was $1.5 million, down from $1.9 million in the same period in 2024, primarily due to decreased sales in key product lines [16][19] - Operating expenses for Q3 2025 were $2.9 million, significantly lower than $7.3 million in Q3 2024, driven by reductions in research and development costs and other expenses [17][20] Strategic Developments - The company has suspended its Juvente cosmeceuticals line due to limited success in e-commerce channels, focusing instead on core business areas [8] - COSCIENS is evaluating its pharmaceutical products, including Macrilen, which did not meet primary endpoints in a recent trial but still provides insights for future development [12] - The company is exploring new market opportunities for its active ingredients and has completed construction of its PGX technology units in Edmonton and Austria [10][11] Corporate Actions - Following the Nasdaq delisting, COSCIENS has applied for quotation on the OTCQB Venture Market, although approval is not guaranteed [4] - The company plans to file a Form 15-F with the SEC to terminate its U.S. reporting obligations, which would take effect 90 days after filing [4][5] - Management is focused on enhancing operational efficiency and reducing costs to maintain competitiveness in the current economic environment [5]

Core Viewpoint - COSCIENS Biopharma Inc. has received director nominations from Goodwood Fund and Puccetti Funds Management Inc. for its upcoming Annual and Special Meeting of Shareholders, indicating potential changes in governance and strategic direction [1][2]. Company Overview - COSCIENS Biopharma Inc. is a life sciences company focused on developing and commercializing a diverse range of cosmeceutical, nutraceutical, and pharmaceutical products, utilizing proprietary extraction technology from renewable plant resources [3]. - The company's product portfolio includes macimorelin (Macrilen®; Ghryvelin®), which is the first and only FDA and EMA approved oral test for diagnosing adult growth hormone deficiency [3]. Market Position - COSCIENS is publicly traded on both the NASDAQ Capital Market and the Toronto Stock Exchange under the ticker symbol "CSCI" [4].